2330 related articles for article (PubMed ID: 18616789)
21. The analysis of the outcomes and factors related to iliac-obturator involvement in cutaneous melanoma patients after lymph node dissection due to positive sentinel lymph node biopsy or clinically detected inguinal metastases.
Zdzienicki M; Rutkowski P; Nowecki ZI; van Akkooi AC; Michej W; Dziewirski W; Świtaj T; Pieńkowski A; Sałamacha M; Bylina E; Eggermont AM
Eur J Surg Oncol; 2013 Mar; 39(3):304-10. PubMed ID: 23298828
[TBL] [Abstract][Full Text] [Related]
22. Elective, therapeutic, and delayed lymph node dissection for malignant melanoma of the head and neck: analysis of 1444 patients from 1970 to 1998.
Fisher SR
Laryngoscope; 2002 Jan; 112(1):99-110. PubMed ID: 11802046
[TBL] [Abstract][Full Text] [Related]
23. Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma.
Visús C; Andres R; Mayordomo JI; Martinez-Lorenzo MJ; Murillo L; Sáez-Gutiérrez B; Diestre C; Marcos I; Astier P; Godino J; Carapeto-Marquez de Prado FJ; Larrad L; Tres A
Melanoma Res; 2007 Apr; 17(2):83-9. PubMed ID: 17496783
[TBL] [Abstract][Full Text] [Related]
24. The tumor biology of melanoma nodal metastases.
Miliotes G; Albertini J; Berman C; Heller R; Messina J; Glass F; Cruse W; Rapaport D; Puleo C; Fenske N; Petsoglou C; Deconti R; Lyman G; Reintgen D
Am Surg; 1996 Jan; 62(1):81-8. PubMed ID: 8540654
[TBL] [Abstract][Full Text] [Related]
25. Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes.
Kuo CT; Hoon DS; Takeuchi H; Turner R; Wang HJ; Morton DL; Taback B
J Clin Oncol; 2003 Oct; 21(19):3566-72. PubMed ID: 12913098
[TBL] [Abstract][Full Text] [Related]
26. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma.
Scoggins CR; Ross MI; Reintgen DS; Noyes RD; Goydos JS; Beitsch PD; Urist MM; Ariyan S; Davidson BS; Sussman JJ; Edwards MJ; Martin RC; Lewis AM; Stromberg AJ; Conrad AJ; Hagendoorn L; Albrecht J; McMasters KM
J Clin Oncol; 2006 Jun; 24(18):2849-57. PubMed ID: 16782924
[TBL] [Abstract][Full Text] [Related]
27. Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma.
van Akkooi AC; Bouwhuis MG; de Wilt JH; Kliffen M; Schmitz PI; Eggermont AM
Br J Surg; 2007 Oct; 94(10):1293-9. PubMed ID: 17702089
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of the RT-PCR positive sentinel node in melanoma.
Temple CL; Snell LJ; Power SM; Parfitt JR; Scilley C; Engel CJ; Shum D; Chakrabarti S; Joseph MG; Lohmann RC; Ainsworth P
J Surg Oncol; 2007 Jun; 95(7):546-54. PubMed ID: 17219388
[TBL] [Abstract][Full Text] [Related]
29. Pathologic assessment of melanoma sentinel nodes: a role for molecular analysis using quantitative real-time reverse transcription-PCR for MART-1 and tyrosinase messenger RNA.
Abrahamsen HN; Sorensen BS; Nexo E; Hamilton-Dutoit SJ; Larsen J; Steiniche T
Clin Cancer Res; 2005 Feb; 11(4):1425-33. PubMed ID: 15746042
[TBL] [Abstract][Full Text] [Related]
30. [Sentinel lymph node biopsy for melanoma: prognostic value and disadvantages in 300 patients].
de Vries M; Jager PL; Suurmeijer AJ; Plukker JT; van Ginkel RJ; Hoekstra HJ
Ned Tijdschr Geneeskd; 2005 Aug; 149(33):1845-51. PubMed ID: 16128183
[TBL] [Abstract][Full Text] [Related]
31. Molecular Staging of Sentinel Lymph Nodes Identifies Melanoma Patients at Increased Risk of Nodal Recurrence.
Kimbrough CW; Egger ME; McMasters KM; Stromberg AJ; Martin RC; Philips P; Scoggins CR
J Am Coll Surg; 2016 Apr; 222(4):357-63. PubMed ID: 26875070
[TBL] [Abstract][Full Text] [Related]
32. Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma.
Badgwell B; Xing Y; Gershenwald JE; Lee JE; Mansfield PF; Ross MI; Cormier JN
Ann Surg Oncol; 2007 Oct; 14(10):2867-75. PubMed ID: 17671814
[TBL] [Abstract][Full Text] [Related]
33. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
[TBL] [Abstract][Full Text] [Related]
34. Molecular test for the detection of tumor cells in blood and sentinel nodes of melanoma patients.
Van der Velde-Zimmermann D; Roijers JF; Bouwens-Rombouts A; De Weger RA; De Graaf PW; Tilanus MG; Van den Tweel JG
Am J Pathol; 1996 Sep; 149(3):759-64. PubMed ID: 8780380
[TBL] [Abstract][Full Text] [Related]
35. Quantitative real-time RT-PCR in sentinel lymph nodes from melanoma patients. Detection of melanocytic mRNA predicts disease-free survival.
Riber-Hansen R; Abrahamsen HN; Sorensen BS; Hamilton-Dutoit SJ; Steiniche T
APMIS; 2008 Mar; 116(3):199-205. PubMed ID: 18377585
[TBL] [Abstract][Full Text] [Related]
36. Prospective evaluation of the prognostic relevance of molecular staging for urothelial carcinoma.
Copp HL; Chin JL; Conaway M; Theodorescu D
Cancer; 2006 Jul; 107(1):60-6. PubMed ID: 16691580
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of detecting micrometastases by tyrosinase RT/PCR in sentinel lymph node biopsies: lessons from 322 consecutive melanoma patients.
Ulrich J; Bonnekoh B; Böckelmann R; Schön M; Schön MP; Steinke R; Roessner A; Schmidt U; Gollnick H
Eur J Cancer; 2004 Dec; 40(18):2812-9. PubMed ID: 15571965
[TBL] [Abstract][Full Text] [Related]
38. Multimarker real-time reverse transcription-PCR for quantitative detection of melanoma-associated antigens: a novel possible staging method.
Arenberger P; Arenbergerova M; Gkalpakiotis S; Lippert J; Stribrna J; Kremen J
J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):56-64. PubMed ID: 18181974
[TBL] [Abstract][Full Text] [Related]
39. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence.
Hoon DS; Bostick P; Kuo C; Okamoto T; Wang HJ; Elashoff R; Morton DL
Cancer Res; 2000 Apr; 60(8):2253-7. PubMed ID: 10786692
[TBL] [Abstract][Full Text] [Related]
40. S-100B: a stronger prognostic biomarker than LDH in stage IIIB-C melanoma.
Wevers KP; Kruijff S; Speijers MJ; Bastiaannet E; Muller Kobold AC; Hoekstra HJ
Ann Surg Oncol; 2013 Aug; 20(8):2772-9. PubMed ID: 23512078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
